Our In Vitro Services Include a Large Cohort of Validated and Well-Characterized Cell Lines
CrownBio offers a variety of in vitro platforms for your oncology drug discovery program.
At CrownBio we are committed to saving you precious time and resources by providing efficient screening platforms and validated cell lines, giving you confidence in your data.
Our large team of international scientists have extensive experience working with Pharmaceutical and Biotechnology companies to support the in vitro pharmacology characterization of lead compounds.
Select from our Collections of Generic or Focused Cancer Cell Lines
OmniPanel™, a genomically diverse collection of more than 500 cancer cell lines for drug response screening
XenoSelect™, a diverse oncogenic in vitro screening panel of over 150 well-validated cell lines, with associated Cell Line Derived Xenograft models ready for in vivo efficacy studies
RNAseq Panel, more than 170 in-house genomically characterized cell lines to correlate mutation status, copy number variation, and expression levels with drug response
A Comprehensive Range of Functional Assays
CrownBio’s extensive tool sets to determine the biological functions of each target, and to help you take go/no go decisions, include a variety of functional assays such as:
- High throughput cytotoxicity screening
- In vitro drug combination studies
- 3D clonogenic assays
- 3D Tumor Growth Assays using PrimePanel cell lines
- Target validation studies
- Adhesion, migration, and invasion assays
- Angiogenesis assays
- Apoptosis studies
- ADCC and CDC analyses
- Cell cycle analysis
- Pharmacodynamics/Pharmacokinetics analysis
Immuno-Oncology In Vitro Screening
Cancer immunotherapy is coming of age as a treatment paradigm, however, development of new immunotherapeutics still faces many challenges. Testing new immuno-oncology compounds in vitro, before moving to the in vivo setting, has proved challenging for many new drugs such as biological agents.
CrownBio offers a wide range of assays and platforms for in vitro testing of immuno-oncology agents, including core immunophenotyping, functional assays, and technologies for the regulation of the tumor microenvironment, allowing you to move with confidence to the next phase of drug development.